it’s all about the increased costs of bigger trials. Looking back at the quarterly trial costs is one thing. I am sure the BOD have a cash flow forecast that takes into account the rebates / options and all costs
If the company says it’s fully funded then who are we to challenge, given that we don’t have the details
That bring said, I do think that there will be a boost to the coffers in the form of a deal with Big Pharm in one form or another, hopefully by the end of quarter 2 2021.
IMU Price at posting:
5.7¢ Sentiment: Buy Disclosure: Held
